Request for Quotation
  • combinatorial blockade against IDO, CTLA-4 and PD-L1 in mi

    CTLA-4 and PD-L1 in mice with brain tumorsDerek A. Wainwright, Alan L. Chang, Mahu 100% of micebearing intracranial tumors were long-term survivors following triple combi

    GET PRICE BY E-MAIL

  • TCD8+TPD-

    bearing recipients. PD-L1 blockade in allogeneic transplant recipients largely restored the GVL efficacy without triggering GVHD, whereas no significant antileukemia effects of P

    GET PRICE BY E-MAIL

  • PD-L1 and HLA Class I Antigen Expression and Clinical Course o

    -TPD-L1 -

    20151028-(PD-L1; also known as B7-H1) checkpoint blockade2, 3, 4 and adoptive T-cell transfusion5 in tumour-bearing mice. Moreover, tumour EZH2 PD-1 and PD-L1 expression by T-cells and ICC cells, respectively. The results of this an mAbs in patients bearing ICC tumors without defects in HLA class I antigen expression.

    GET PRICE BY E-MAIL

  • Effects of TGF[bgr]R2, IgA, PD-L1 and IL-10 ablations on tumou

    Tgfbr2ΔBor Iga−/− MC tumour-bearing mice (n = 4 7 per group) analysed for PD-L1 expression, revealing lower PD-L1 surface expression on Tgfbr2Δ and Iga−/− B cells a

    GET PRICE BY E-MAIL

  • 3 class="res-title">The increase of circulating PD-L1-expressing CD68+macrophage i

    The increase of circulating PD-L1-expressing CD68+macrophage in

    PD-L1 is selectively overexpressed on some TAM compared that of benign ovarian dise bearing host. J Immunother. 2012;35:544 54. Heusinkveld M, de Vos van Steenwijk PJ

    GET PRICE BY E-MAIL

  • Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blocka

    . PDL-1 expression was detected in Myc-CaP murine prostate tumors growing in immun bearing the corresponding antigen (hPSMA). CAR T cell therapy in solid tumors has not

    GET PRICE BY E-MAIL

  • COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tum

    PD-L1-expressing cells were immunosuppressive and were capable of eliminating CD8 T cells in vitro. Tumor-infiltrating PD-L1(+) cells isolated from tumor-bearing mice also exe

    GET PRICE BY E-MAIL

  • 3 class="res-title">Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist fo

    Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for

    PD-L1 pathway. The optimized compound DPPA-1 could bind PD-L1 at an affinity of 0.51 μM in vitro. A blockade assay at the cellular level and tumor-bearing mice experiments

    GET PRICE BY E-MAIL

  • PD-L1CTL

    meanwhile the antitumor activity of PD-L l mAb and antigen specificCTL in vivo was evaluated in BALB/c nude mice bearing lung cancer. Part I:Establishment of lung cancer cell li

    GET PRICE BY E-MAIL

  • PD-L1CTL.pd

    meanwhile the antitumor activity of PD-L l mAb and antigen TL in vivo was evaluated in BALB/c nude mice bearing lung cancer.Part I:Establishment of lung cancer cell line transfec

    GET PRICE BY E-MAIL

  • Blocking Programmed Death-1 Ligand-PD-1 Interactions by Loca

    PD-L1 and PD-L2 genes were expressed in tumor and vicinal muscle tissues of tumor-bearing mice and the expression level was significantly increased if a higher dosage of pSL

    GET PRICE BY E-MAIL

  • carcinoma-associated fibroblasts synergizes with anti PD-L1 i

    bearing mice had cancer cell-specific CD8 cells,the mice, like human patients with PD and α-programmed cell death (α-PD-L1).Immune control of PDA growth was achieved

    GET PRICE BY E-MAIL

  • Curis Expands Cancer Drug Pipeline With Small Molecule PD-L1

    PD-L1/VISTA and IRAK4 programs resulted in an aggregate one-time payment of $6 million by Curis to Aurigene in exchange for an exclusive, royalty-bearing license to develop,

    GET PRICE BY E-MAIL

  • Local and systemic modulation of the PD-L1 pathway is a nove

    PD-L1/2 expressing dendritic cells (DC) andmyeloid derived suppressor (MDSC) cells in the blood ofENZ resistant tumor bearing mice compared to those withCRPC. We also fo

    GET PRICE BY E-MAIL

  • and the Expression of PD-L1 Predict Poor Prognosis of

    blocking of the PD1 pathway induced tumor regression or prolonged survival of tumor bearing mice [ 24 25 ]. Recent reports have shown that anti-PD1 and anti-PD-L1 antibody au

    GET PRICE BY E-MAIL

  • Acid-Activatable Versatile Micelleplexes for PD-L1 Blockad

    photodynamic immunotherapy with the POP PD-L1 micelleplexes, and H&E examination of the major organs at the end of antitumor study of the B16-F10 tumor-bearing C57BL

    GET PRICE BY E-MAIL

  • antitumor immunity and facilitates anti-PD-L1 efficac

    bearing mice (fig. S5C). We thus concluded that the observed systemic immunological e Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 eff

    GET PRICE BY E-MAIL

  • PD-L1/CD274 Antibody 17952-1-AP Proteinte

    PD-L1 (programmed cell death ligand 1, also known as CD274 or B7-H1) is the first me Sequential Cisplatin/Radiotherapy on Immune Status in Lung Tumor-Bearing C57BL/6 M

    GET PRICE BY E-MAIL

  • PD-L1CTL

    meanwhile the antitumor activity of PD-L1mAb and antigen specific CTL in vivo was evaluated in BALB/c nude mice bearing lung cancer.PartⅠ: Establishment of lung cancer cell

    GET PRICE BY E-MAIL

  • Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathwa

    Background Blockade of the programmed death-1 (PD-1)/PD-ligand 1 (PD-L1) pathway can delay tumor growth and prolong the survival of tumor-bearing mice. The extracellular i

    GET PRICE BY E-MAIL

  • PD-1 antibody:PD-1

    PD-L1, Maintainsperipheral tolerance, protecting tissues from autoimmune damage Ma bearing mice Tumor injected I.V. mCT-011(BAT) administered I.V. 10ug/mouseonce da

    GET PRICE BY E-MAIL